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Abstract
Background: Aquilaria crassna has been used in traditional Asian medicine to treat vomiting, rheumatism, asthma,
and cough. Furthermore, earlier studies from our laboratory have revealed that the essential oil extract from
agarwood inhibited colorectal carcinoma cells. Despite of the wide range of ethno-pharmacological uses of
agarwood, its toxicity has not been previously evaluated through systematic toxicological studies. Therefore, the
potential safety of essential oil extract and its in vivo anti-tumor activity had been investigated.
Methods: In the acute toxicity study, Swiss female mice were given a single dose of the essential oil extract at
2000 mg/kg/day orally and screened for two weeks after administration. Meanwhile, in the sub-chronic study, two
different doses of the extract were administered for 28 days. Mortality, clinical signs, body weight changes,
hematological and biochemical parameters, gross findings, organ weights, and histological parameters were
monitored during the study. Other than that, in vivo anti-tumor study was assessed by using subcutaneous tumors
model established in nude mice.
Results: The acute toxicity study showed that the LD50 of the extract was greater than 2000 mg/kg. In the
repeated dose for 28-day oral toxicity study, the administration of 100 mg/kg and 500 mg/kg of essential oil per
body weight revealed insignificant difference in food and water intakes, bodyweight change, hematological and
biochemical parameters, relative organ weights, gross findings or histopathology compared to the control group.
Nevertheless, the essential oil extract, when supplemented to nude mice, caused significant growth inhibition of
the subcutaneous tumor of HCT 116 colorectal carcinoma cells.
Conclusion: Collectively, the data obtained indicated that essential oil extract from agarwood might be a safe
material, and this essential oil is suggested as a potential anti-colon cancer candidate.
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Background
There is some truth to the old adage that the therapeutic
use of natural products and their derivatives is as old as
the human race. The ancient civilizations provided writ-
ten evidences for the use of natural sources to treat vari-
ous illnesses. In fact, the oldest description of medical
document dated 4000 years ago, depicted on a Sumerian
clay table with a list of the most valuable medicinal
plants [1]. The knowledge and historical experiences of
medicinal plant have been passed from one generation
to the next, interpreted as accumulative body and form
the basis of traditional and modern medicine.
According to the World Health Organization (WHO),
about 80 % of population in the developing countries re-
lies on traditional herbal medicine for primary health care
needs. Recently, a wide range of plant-derived phytochem-
ical components and their synthetic derivatives have been
suggested for cancer treatment. Moreover, it has been
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estimated that 25 %-48 % of the currently approved
therapies by the Food and Drug Administration (FDA) are
derived from plants. Surprisingly, more than 10,000 phy-
tochemicals have been identified and used in cancer treat-
ment due to their privileged structure and broad spectrum
of biological activities [2, 3]. Phytochemicals, such as pac-
litaxel, vincristine, and camptothecin, have become major
and significant sources for chemotherapy in cancer treat-
ment protocols, which provided the most successful alter-
native and complementary anti-cancer regimen [4]. Also,
there is the worldwide green revolution that is generated
from the notion that medicinal plants are safer and less
harmful to the human body than synthetic drugs, and be-
sides, there is wide consensus that the advantage of nat-
ural components over synthetic compounds is less toxic
based on their long term use [5].
Nevertheless, failing to identify the chemical profile of
plants and the safety assessment may lead to deleterious
effects on health. Furthermore, it has been well-
documented that from about 1,500,000 plants investi-
gated, most of them contained toxic constituents,
indicating that medicinal plants should be used with pre-
caution and toxicology investigation is indeed vital to in-
crease the knowledge of ethnopharmacological uses of
plants [6].
The genus of Aquilaria (Thymelaeceae) is comprised
of approximately 15 species distributed across the rain
forests of Southeast Asia, where only 8 species were re-
ported for agarwood formation. Agarwood is also known
as gaharu in Malaysia, eaglewood and krissana in
Thailand, Oudh in Middle East, chen-xiang in Chinese,
and jin-koh in Japan [7]. In general, species like Aqularia
malaccensis (agallocha), A. crassna, and A. sinensis have
been widely explored for their chemical constituents
(resin and essential oils), while less focus had been given
to their pharmacological activities. The products of
Aqularia, including Agarwood oil, leaves, and seeds,
were prescribed in traditional Asian medicine to treat
vomiting, rheumatism, and asthma. In Malaysian trad-
itional medicine, (gaharu) used to be mixed with coco-
nut oil as an ointment to treat body pain [8]; (jin-koh)
has been used for traditional medicine in Japan as a
sedative or tranquilizer in detoxifying the body and
maintaining stomach health [9]. In addition, much atten-
tion has been paid to the phytochemical investigation
and the characterization of the active components from
this plant in these recent years. Aquilaria crassna, in
addition, has been identified as convenient and useful
sources of bioactive constituents, such as phenolic, fla-
vonoids, benzophenones, xanthones, and Sesquiterpenes
[10]. In fact, several studies have looked into the bio-
logical activities of Aquilaria crassna. In particular, it
seemed to possess anti-ischemic [11], anti-fungal [12],
and anti-bacterial effects [13]. Earlier communications
from this laboratory reported the extraction and the
purification of the essential oil derived from Aquilaria
crassna and the active principle was identified as well.
The biological investigation revealed potent antioxidant
and in vitro anti-cancer properties against colorectal car-
cinoma cells (HCT 116) and pancreatic cancer cells
(MIA PaCa-2), which had been mediated via apoptotic
mechanism [14–16].
Despite of the broad spectrum of biological activities,
no study had reported on the toxicological profiles of
Aquilaria crassna essential oil. With this in mind, the
present study had been designed to bridge the informa-
tional gaps with the following objectives:
 To study the acute and the sub-chronic oral toxicity
profile of A. crassna essential oil in Swiss mice.
 To study the anti-tumor efficacy of A.crassna essential
oil by employing subcutaneous tumor model of
human colorectal cancer.
Methods
Agarwood material and extraction of essential oil
Fresh sample of A. crassna stem bark was obtained from
a local farm in Kajang, Selangor, Malaysia, in the year
2014. In addition, flowers and leaves with twigs were
collected for taxonomical authentication and were de-
posited at the School of Biological Sciences, USM (Ref.
No. USM/122083). The bark of A. crassna was cleaned
thoroughly, cut into small slices, and ground mechanic-
ally. The ground material of the stem bark (500 g) was
macerated with distilled water (5 L) at room temperature
(25 ± 2 °C) for 1 week. Finally, hydrodistillation was
employed on the extract for 48 h at boiling temperature
of water. Essential oil (EOs) was obtained by using the
Clevenger-type apparatus. The EO was collected as pale-
yellow liquid with 12.6 g yield.
Toxicity studies
Experimental animals
Male and female Swiss mice at 8-12weeks (25-30 g) were
obtained from the animal house facility of USM. The an-
imals were kept in the transit animal house at the School
of Pharmaceutical Sciences to acclimatize them for five
days. During this period, the mice were kept in venti-
lated cages at 12 h light cycle with continuous supply of
food and water. The procedures described in this study
were approved by the USM Animal Ethics Committee
with the reference number of USM/2014/ (94) (674).
Acute toxicity in mice
A limit test was performed according to the Fixed Dose
Procedure of the OECD guideline 425 to evaluate the
oral toxicological profiling of the essential oil extract
[17]. Five healthy Swiss female mice were randomly
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selected, marked to permit individual identification, and
kept in their cages for at least 5-7 days prior to dosing for
acclimatization to the laboratory conditions. 2000 mg/kg
body weight of extract was administrated to overnight
fasted mice in a single dose via oral gavage (the maximum
administered volume was 10 ml/kg). After the essential oil
was administered, food, but not water, was withheld for 3-
4 hrs. According to the guideline, one animal at a time
was treated with 2000 mg/kg and the animal was moni-
tored for 48 hours. When the animal did not die, then an-
other four animals were treated at the same dose and
were monitored for 14 days. In case of death of the first
animal within 48 hours of treatment, the main test proto-
col was adhered. All animals were weighed on 0, 7th, and
14th days and were observed for any signs or symptoms
of toxicity and/or mortality. The visual observations were
recorded, including the changes in skin and fur, eyes and
mucous membranes, as well as in the behavioral pattern,
such as alertness and positioning of the animals.
Sub-chronic toxicity in mice
A sub-chronic repeated dose (28 days) study in mice
was conducted according to the OECD 407 guideline
[18]. Healthy male and female Swiss mice were ran-
domly divided into three groups, comprising of 10 ani-
mals in each group. The essential oil was emulsified in
Tween-80 at 1 % before it was administrated to the ani-
mals. The essential oil extract was administered orally
and daily for 28 days in single doses of 500 mg/kg
(group I) and 1000 mg/kg (group II), whereas the
control (group III) received only aqueous with (1 %
Tween-80). Body weight was recorded at 0, 7th, 14th,
and 28th days. Along with food and water consump-
tions, toxic manifestations and mortality were also moni-
tored daily throughout the study period. At the end of
the experiment, all mice were anesthetized via carbon di-
oxide inhalation and their blood samples were collected
via cardiac puncture into non-heparinized and EDTA con-
taining tubes for biochemical and hematological analyses,
respectively. After blood collection, the animals were
Fig. 1 Body weight changes of male (a) and female (b) Swiss mice
during the 28-day toxicological assessment. The vehicle, water
(10 ml/kg/day), was administered to mice in the control group. No
significant differences were detected between the treated (100 and
500 mg/kg. All values are expressed as the mean ± SD (n = 10)
Table 1 Effects of the sub chronic oral administration of EOs on hematological parameters in Swiss mice
Parameters Control EOs 100 mg/kg EOs 500 mg/kg
Male Female Male Male Male Female
Hemoglobin (g/dL) 17.00 ±1.25 15.00 ± 1.50 16.00 ± 1.55 16.50±2.52 15.40±2.70 16.00 ±2.62
Total Red Blood Cell (1012/L) 11.70±0.24 10.19 ± 0.25 11.80±0.25 11.62±0.14 11.67±0.31 13.50±0.50*
Red cell distribution width (%) 22.10±1.33 20.30±0.90 22.30±1.11 20.39±0.11 23.00±1.25 21.94±1.84
Total White Blood Cell (109/L) 9.30±2.51 8.98 ± 1.22 9.50±1.69 8.61±2.70 8.44±1.95 6.93±1.00*
Neutrophils (%) 3.90±2.11 2.70 ± 2.29 3.50±2.99 2.50±2.11 2.60±2.11 3.90±2.81
Lymphocytes (%) 6.40±2.10 5.88 ± 2.00 6.50±2.13 6.33±2.14 10.70±2.52 6.52±2.12
Eosinophils (%) 0.05±0.02 0.00 ± 0.00 0.03±0.09 0.08±0.05 0.03±0.25 0.08±0.07
Monocytes (%) 0.60±0.10 0.60 ± 0.40 0.33±0.50 0.80±0.45 0.70±0.40 0.70±0.50
Basophils (%) 0.00 ± 0.00 0.01 ± 0.02 0.00 ± 0.00 0.00 ± 0.00 0.01 ± 0.05 0.50 ± 0.05
Packed Cell Volume (%) 0.52±0.5 0.75 ± 0.58 0.55±0.42 0.70±0.50 0.47±0.44 0.72±0.25
Mean Corpuscular (fl) 44.00±0.63 50.00 ± 0.76 47.00±0.40 51.00±0.26 44.00±0.60 53.40±0.12
Mean Corpuscular Hb (pg) 15.00±0.52 18.40 ± 0.18 15.00±0.50 17.99±0.55 14.00±0.82 15.49±0.49
Platelet count(109/L) 1419.10±96.69 1293.00±85.49 1221.50±89..27 1167.70±30.26 1292.00±10..33 1375.80±28.20
Values are presented as mean ± SD, (*P < 0.05)
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sacrificed via cervical dislocation for isolation of organs to
observe histopathological changes. The liver, kidney, lung,
brain, spleen, and heart were excised, weighed using ana-
lytical lab balance (Mettler-Toledo AX-204, Japan), exam-
ined macroscopically, and finally, fixed in 10 % buffered
neutral formalin for histopathological examination.
Hematology indexes
The blood was analyzed within one hour by using Sysmex-
XT-1800 Automated Hematology Analyzer, Germany
Analyses, performed at Gribbles lab (Pinang Malaysia). The
hematology indexes included red blood cell (RBC),
white blood cell (WBC), neutrophil, lymphocyte, eo-
sinophil, monocyte, basophil, hemoglobin concentration
(Hb), hematocrit (Ht), mean corpuscular volume
(MCV), mean corpuscular hemoglobin (MCH), mean
corpuscular hemoglobin concentration (MCHC), and
platelet count (Plt).
Clinical biochemistry indexes
The blood samples were centrifuged immediately after
collection at 3000 rpm for 15 min, and the supernatant
was collected as the serum. The clinical biochemistry in-
dexes were measured within 1 h by using an automated
Olympus 640 Biochemistry Analyzer, Japan Analysis,
performed at Gribbles lab. (Pinang, Malaysia). With that,
alkaline phosphatase (ALP), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), lactate de-
hydrogenase, creatin phosphokinase, total protein, total
albumin, albumin/globulin ratio, phosphorus, calcium,
sodium, potassium, chloride, as well as total and conju-
gated bilirubin, were measured.
Histopathological study
As for histopathological study, 3 randomly selected mice
from each experimental group were euthanized and the
named organs were harvested and fixed in 10 % buffered
neutral formalin for 48 hours, and then with bovine
Table 2 Effects of the sub chronic oral administration of EOs on hematological parameters in Swiss mice
Parameters Control EOs 100 mg/kg EOs 500 mg/kg
Male Female Male Female Male Female
Total protein (g/dL) 6.00 ± 0.89 5.30 ± 1.10 5.67 ± 1.61 5.59± 1.88 6.6 0± 1.38 6.00 ± 1.99
Albumin (g/dL) 3.05 ± 0.68 3.33 ± 0.58 3.00 ± 0.55 4.00 ± 1.18 4.55 ± 058 3.89 ± 0.50
Globulin (g/dL) 3.32 ± 0.22 2.61 ± 0.39 3.00 ± 0.32 3.20 ± 1.94 3.34 ± 0.53 3.98 ± 0.92
Total bilirubin (U/L) <2.00 <2.00 <2.00 <2.00 <2.00 <2.00
Alkaline phosphatase(mmol/l) 143.42 ± 12.74 134.23 ± 3.08 144.73 ± 18.08 131.12 ± 4.50 145.0 ± 20.40 126.9 ± 5.29
Urea (mmol/l) 7.20 ± 0.15 7.19 ± 0.29 6.30 ± 0.2 6.33± 0.22 6.00 ± 0.23 5.19 ± 0.90*
Potassium (mmol/l) 7.50± 0.07 5.92 ± 0.11 6.10 ± 0.04 5.55 ± 0.09 7.50± 0.05 6.36 ± 0.68
Sodium (mmol/l) 149.00 ± 0.12 135.53 ± 0.92 147.50 ± 0.40 139.33 ± 1.10 147.80 ± 0.41 144.33 ± 1.00
Chloride (mmol/l) 116.14 ± 3.29 100.33 ± 0.13 109.00 ± 2.93 100.00 ± 0.50 110.00± 2.10 111.39 ± 1.09
Creatinine (μmol/l) 26.00 ± 1.14 27.11 ± 1.11 27.66± 1.00 27.77 ± 1.10 29.90 ± 1.97 27.00 ± 1.23
Uric acid (μmol/l) 0.17 ± 0.02 0.19.5± 0.06 0.18 ± 0.05 0.20 ±0.05 0.27 ± 0.09* 0.20± 0.09
Total cholesterol(mg/dl) 169.30±9.80 131.33±7.22 122.58±11.10 119.12±5.05 133.00±19.99 99.20±9.90*
Triglyceride (mg/dl) 155.32±6.44 144.50±13.7 132.40 ±7.68 153.30±11.4 129.90±10.50 123.80±7.25
HDL cholesterol (mg/dl) 76.22±6.04 66.80±10.50 68.90±11.30 65.60±11.61 75.52±12.58 71.15± 13.55
Values are presented as mean ± SD, (*P < 0.05)
Table 3 Effects of the subchronic oral administration of EOs on organ weights in Swiss mice
Organ
weight (g)
Control EOs 100 mg/kg EOs 500 mg/kg
Male Female Male Female Male Female
Brain 0.40 ± 0.03 0.45 ± 0.07 0.40 ± 0.02 0.46 ± 0.02 0.40 ± 0.03 0.45 ± 0.03
Heart 0.25 ± 0.02 0.19 ± 0.01 0.24 ± 0.03 0.18 ± 0.01 0.24 ± 0.04 0.19 ± 0.01
Liver 2.36 ± 0.55 2.28 ± 0.55 2.22 ± 0.10 2.56 ± 0.19 2.34 ± 0.08 3.10 ± 0.21*
Spleen 0.25 ± 0.02 0.20 ± 0.02 0.20± 0.02 0.21± 0.02 0.20 ± 0.02 0.23 ± 0.02
Kidney 0.29 ± 0.01 0.32 ± 0.01 0.26 ± 0.1 0.25 ± 0.1 0.24 ± 0.03* 0.23 ± 0.07*
Lungs 0.25 ± 0.02 0.23± 0.02 0.24 ± 0.02 0.22 ± 0.02 0.23 ± 0.02 0.24 ± 0.03
Pancreas 0.30±0.05 0.35±0.04 0.29±0.03 0.36±0.02 0.31±0.04 0.36±0.04
Values are presented as mean ± SD, (*P < 0.05)
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solution for 6 hours, and processed for paraffin embed-
ding. Sections of 5 μm thickness were taken by using a
microtome, processed in alcohol-xylene series, and were
stained with both hematoxylin and eosin.
In vivo anti-tumor model
Experimental animals
Athymic NCR nu/nu nude mice were obtained from
Taconic Farms Inc., USA. According to the supplier, the
autosomal recessive nude gene in homozygous (nu/nu)
mice caused the lack of fur and an abnormal thymus.
The deficiency in T cell function allowed athymic mice
to accept and develop xenografts tumor model. The
mice of the same gender were housed in specific patho-
gen free (SPF) cages supplied with high efficiency par-
ticulate air (HEPA) filters. Free access to autoclaved food
and water was provided and the autoclaved bedding was
changed twice weekly. The procedures were approved by
the USM Animal Ethics Committee with the reference
number USM/2014/ (94) (672).
In vivo anti-tumor activity
Twenty four nude mice aged 6–8 weeks with an average
weight of 25 g were injected subcutaneously in the right
flank with 5 × 106 HCT 116 cells in 150 μl RPMI. After
7–10 days of tumor initiation, the animals were divided
randomly into 4 groups of 6–8 animals. Group 1 re-
ceived 0.2 ml of distilled water with 0.1 % tween-80 as
control, while Groups 2, 3, and 4 received oral treat-
ments with 200, 100, and 50 mg/kg bodyweight of essen-
tial oil extract. The tumor size and the body weight were
recorded before starting the treatment and at 5 days
interval until the end of the experiment. Treatment of
animals was performed orally via oral gavages (wt/wt)
once a day for a period of 6-8 weeks. The tumor size
was calculated as described previously [19, 20] by apply-
ing the formula: Tumor volume (mm3) = (((W + L) / 2) ^
3) × 2; where W is the width and L is the length. For tu-
mors with more than one lobe, the tumor size was cal-
culated through the summation of the size of the
individual lobes. Also, the following value was calculated:
% ΔT/ΔC, where, ΔT = T − Δ0 and ΔC = C − Δ0 (Δ0 is
the average tumor volume at the beginning of the treat-
ment, whereas T and C are the tumor volumes at a spe-
cified day for treated and control groups, respectively).
Normally, the ΔT/ΔC value in percent is used as an in-
dication of anti-tumor effectiveness, and a value of ΔT/
ΔC ≤ 42 % is considered as significant anti-tumor activity
by the Division of Cancer Treatment, NCI, NIH [21]. At
the end of the experiment, the animals were euthanized
Fig. 2 Representative microscopic findings for the liver section of Swiss mice, males (left) and females (right) treated orally with 100 and 500 mg/kg
essential oils EOs or negative control N.C (water + 1 % Tween-80) for 28 days. The methods applied hematoxylin and eosin method (400 x)
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with CO2, and followed by cervical dislocation. The sub-
cutaneous tumors were excised and the tumors were
preserved in 4 % paraformaldehyde. Cross sections were
prepared and stained with eosin/hematoxylin. The extent
of apoptosis/necrosis and the number of blood vessels were
examined in 25 microscopic fields at 20x magnification.
Statistical analysis
The results are presented as mean ± SD. The differences
between groups were compared via One-way ANOVA, and
were considered significant at P < 0.05. The statistical ana-
lysis was carried out by using GraphPad prism version 6.
Results
Acute toxicity study
The acute toxicity test allowed the estimation of median le-
thal dose (LD50), which represented the dose that killed
50 % of the tested population, which had been used to ap-
preciate the toxicity of the samples. The study also provided
useful information concerning the effect of acute exposure
of test animals to high doses of extracts under investigation.
Treatment of female and male Swiss mice with essential oil
of A.crassna did not produce treatment-related mortality at
the limit test dose (2000 mg/kg), and besides, throughout
the 14 days observation period, no significant changes had
been discovered in the behavior, such as apathy, hyperactiv-
ity, dizziness, vomiting, diarrhea, excessive salivation, loss
of fur, anxiety, convulsions, lethargy, and morbidity,
among the tested animals. Furthermore, no abnormal
changes attributable to treatment had been noticed in
body weights and treatment related changes like res-
piration rate and heart rate. Thus, EOs had been
found to be safe at the dose level of 2000 mg/kg and
therefore, the LD50 value for oral toxicity had been
considered to be more than 2000 mg/kg.
Sub-chronic toxicity study
The effect of 28-day oral administration of the EOs on
general behavior, hematological, and biochemical param-
eters in Swiss mice showed no signs of toxicity, such as
piloerection, diarrhea, sedation, loss of fur, and alter-
ations in locomotors activity or mortality, as recorded
during the 28 consecutive days of treatment via oral
route with the EOs at the doses of 100 and 500 mg/kg.
The body weight gain of both genders was not affected
by EOs treatment compared to control group (Fig. 1).
However, slight changes in food and water consumptions
in both sexes were observed in treated groups during
the treatment period compared to control group.
Fig. 3 Representative microscopic findings for the kidney section of Swiss mice, males (left) and females (right) treated orally with 100 and 500 mg/kg
essential oils EOs or negative control N.C (water + 1 % Tween-80) for 28 days. The methods applied hematoxylin and eosin method (400 x)
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Hematological and biochemical parameters
The results of the hematological profile of mice exposed
to sub-acute treatment with the EOs of A.crassna (100
and 500 mg/ml) and control group are shown in Table 1.
However, no changes had been recorded in the
hematological indices in either sex. Similarly, the bio-
chemical parameters are represented in Table 2, where
no significant deviations had been found between the
treated groups and the control of parameters tested.
Morphological parameters
Microscopic examination of liver, spleen, kidney, lung,
pancreas, brain, and heart cross sections did not exhibit
any obvious changes in the color or the texture when
compared to those of the control group. The organ weight
was calculated per animal at the time of euthanasia. The
related data are depicted in Table 3. The microscopic
examination of organs indicated the presence of fat in the
liver of females in both treated groups with EOs, whereas
the liver of male mice treated with EO did not show any
alteration (Fig. 2.2). Furthermore, the kidneys of male
mice treated with EO did not show any changes, but slight
lymphocytic infiltrate was observed in the kidneys of
female mice treated with EOs (500 mg/kg) (Fig. 2.3).
Other than that, lung (Fig. 2.4) and spleen (Fig. 2.5)
histology of the treated mice exhibited a normal architecture
structure as found in the control group (Figs. 3, 4 and 5).
In vivo anti-tumor study of A. crassna essential oil
towards colorectal cancer
The in vivo anti-colon cancer effect of the EOs extract
was investigated on the HCT 116 subcutaneous tumor
model established in NCR nu/nu nude mice. The results
are presented as average tumor size ± SD (n = 6). The
treatment with the EOs extract caused significant reduc-
tion in the tumor size compared to those in the un-
treated group (Fig. 6-a). Moreover, data analysis was
performed by considering the tumor size recorded in the
first week interval and showed that significant reduction
in tumor size was achieved after 8 weeks. Nonetheless, a
significant ΔT/ΔC = 0.37 %( P < 0.05) anti-tumor activity
of EOs (100 mg/kg) on 8-week post-cell inoculation day
had been recorded. At a dose of (200 mg/kg) on the
sixth week post–cell inoculation day, the EOs showed
profound activity (0.24 %, P < 0.01). Moreover, the
analysis of the tumor cross sections revealed apparent
differences in the extent of necrotic regions between
the treated and untreated tumors (Fig. 6-b). In
addition, the histological feature of the tumors excised
from untreated animals showed a high number of
Fig. 4 Representative microscopic findings for the lung section of Swiss mice, males (left) and females (right) treated orally with 100 and 500 mg/kg
essential oils EOs or negative control N.C (water + 1 % Tween-80) for 28 days. The methods applied hematoxylin and eosin method (400 x)
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blood vessels with less necrosis and apoptosis with a
compact layer of cells. Meanwhile, in animals treated
with EOs, the tumor tissues showed loss of cell com-
pactness and severe necrosis with areas of low density
of blood vessels, as well as many pools of tumor cells.
The changes in body weight and tumor volume are
depicted in Fig. 7.
Discussion
One of the major obstacles in the use of medicinal plants
is the lack of scientific evidence and clinical data about
their efficiency and safety assessment. However, traditional
use does not ensure the safety and effectiveness of these
mixtures. This is the reason for this study to look into the
acute and sub-acute toxicity of the hydrodistillation
extract of A.crassna EOs on Swiss mice. The results ob-
tained from the acute test did not induce toxicity signs in
the mice after single administration of EOs at the dose of
2000 mg/kg. This suggests that LD50 more than 2000 mg/
kg exhibited a characteristic of low toxicity [22]. Conse-
quently, sub-chronic toxicology study was conducted in
order to determine the long-term effect of EOs in animals.
Oral administration at repeated-doses (28 days) of the
EOs in mice of both sexes did not reveal any signs of mor-
bidity or mortality. Moreover, there was infrequent change
in food and water consumptions among the treated
groups of both sexes, but these changes did not affect the
weights of the body and the organs of the mice during the
treatment period (Fig. 1). Furthermore, it showed that
some extracts from plants have the ability to alter body
weight gain and organ weight parameters through their
cumulative effects. Any changes of these parameters indi-
cate a toxic effect of the plant extracts [23]. With that, the
results suggested that the EOs extract of A.crassna did not
produce any side effect on these parameters. During the
sub-chronic toxicity investigation, a significant (P < 0.05)
increase in total red blood cells (RBC) in female animal
treated with 500 mg/kg was observed in hematological
analysis; suggesting that the oral administration of EOs
had no effect on the circulating peripheral blood cells or
on their production. However, the total white blood cells
(WBC) displayed a slight decrease in female animal
treated with 500 mg/kg; indicating the role of daily admin-
istration of EOs in weakening the immunological activity
of Swiss mice [24]. Meanwhile, in the analysis of biochem-
ical parameters, the daily oral administration of the EOs
extract did not exhibit any changes in total protein, albu-
min, creatinine, urea, total cholesterol, and triglyceride in
the treated groups of both sexes. Only male animal treated
with EO of 500 mg/kg had a significant increase (P < 0.05)
in the level of uric acid when compared to the control
group. In the macroscopic appearance of the organs,
Fig. 5 Representative microscopic findings for the spleen section of Swiss mice, males (left) and females (right) treated orally with 100 and 500 mg/kg
essential oils EOs or negative control N.C (water + 1 % Tween-80) for 28 days. The methods applied hematoxylin and eosin method (400 x)
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Fig. 6 The subcutaneous tumors in NCR nude mice (a): Untreated group (1), treated group with EOs at 50 mg/kg (2), 100 mg/kg (3), 200 mg/kg
(4). Cross sections of tumor tissues (b): untreated animals (1), treated animals with 50 mg/kg (2), 100 mg/kg (3), 200 mg/kg. The tissues were
stained with Hematoxylin-eosin. (B.V) refers to blood vesicles, (N) refers to necrotic cells and (V) refers to viable tumor cells
Fig. 7 a Body weight changes of nude mice during the 8 weeks of anti-tumor study. b Analysis of tumor size versus time (days) after treatment
with the EOs extracts compared to the untreated group. Values are presented as mean ± SD
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animals treated with EOs did not produce abnormal signs
in internal organs. Only the female mice, nonetheless,
showed an increase in the liver relative weight and a de-
crease in the kidney relative weight. Moreover, fat was de-
tected in the liver and discrete lymphocytic infiltrate in
the kidneys of female mice treated with EOs. It is possible
that the increase in liver relative weight among female
mice had been due to the presence of fat. However, no
side effect was found on the usual biomarkers of liver and
kidney toxicity; suggesting that EOs did not cause adverse
effect to these organs. Generally, the boundary between
toxic and non-toxic extracts depends on several aspects,
such as the strength of secondary metabolites, the quan-
tity consumed, part of the plant, and the extraction
method.
Commonly, the aqueous extracts seem overall to be
less toxic than organic extracts, as the relative low tox-
icity in the aqueous extracts relies on the fact that they
contain a wide class of phytochemical components in a
similar way to their existence in natural form and hence,
exhibit less risk of side effect [23]. The chemical analysis
of hydrodistillation extract for A.crassna stem bark also
demonstrated versatile classes of sesquiterpenes and
polyphenols [15], and this is also true for the species of
Aquilaria genus, in which these phytochemical compo-
nents were identified as the main constituents [25]. On
top of that, it has been reported that plant-derived ex-
tracts containing a wide range of phytochemicals con-
stituents that exhibit strong cytotoxicity against cancer
cells, and the major part of this activity is from the addi-
tive and the synergistic effects of phytochemicals in the
plant extract [26, 27]. One obvious drawback in medi-
cinal plants research, however, is that the majority of its
biological activity is conducted in vitro, with little regard
for the in vivo study. Thus, it is essential to have credible
experimental models that can mimic the native tumor
microenvironment. This is the key point when aiming to
translate data from in vitro to in vivo and from trad-
itional point of view to pre-clinical application [28]. In
parallel with our previous in vitro data, the second sig-
nificant findings has significantly been associated to the
in vivo anti-tumor effects of EOs using an established
colorectal cancer model of subcutaneous xenograft. As a
result, we found that the growth of colorectal tumors in
nude mice was significantly inhibited by EOs treatment
for 8 weeks, with 200 mg/kg daily dosage being the most
effective dosage. Indeed, several lines of evidence indi-
cated that plant-derived bioactive compounds can be
exploited to regulate the cancer cells by targeting multiple
signaling pathways that are implicated in the consolidation
and the maintenance of tumor microenvironmental fea-
tures [29, 30]. Besides, the anti-tumor activity of EOs may
be explained due to the cytotoxicity effect on the colorec-
tal cancer cell HCT 116 as evident by the morphological
feature of shrinking tumor, as well as the presence of nec-
rotic/apoptotic regions in subcutaneous tumors of treated
animals, or due to the reduction found in the intratumor
blood vessels, as evident by the remarkable reduction in
tumor vascularization in treated groups.
Conclusion
The present study demonstrated that EOs is safe with
LD50 above 2000 mg/kg. The histopathological variations
revealed no clinically relevant changes, since they oc-
curred in non-generalized patterns in both treated mice
and control. Moreover, the results highlighted the pos-
sible application of EOs in colorectal cancer prevention/
treatment and further laid a solid foundation for pre-
clinical use in animal.
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